Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
Article Details
- CitationCopy to clipboard
Powers C, Aigner A, Stoica GE, McDonnell K, Wellstein A
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth.
J Biol Chem. 2002 Apr 19;277(16):14153-8. Epub 2002 Jan 23.
- PubMed ID
- 11809760 [ View in PubMed]
- Abstract
Glioblastoma multiforme is the most common highly aggressive human brain cancer, and receptor tyrosine kinases have been implicated in the progression of this malignancy. We have recently identified anaplastic lymphoma kinase (ALK) as a tyrosine kinase receptor for pleiotrophin, a secreted growth factor that is highly expressed during embryonic brain development and in tumors of the central nervous system. Here we report on the contribution of pleiotrophin-ALK signaling to glioblastoma growth. We found ALK overexpressed in human glioblastoma relative to normal brain and detected ALK mRNA in glioblastoma cell lines. We reduced the endogenous ALK in glioblastoma cells by ribozyme targeting and demonstrated that this prevents pleiotrophin-stimulated phosphorylation of the anti-apoptotic protein Akt. Furthermore, this depletion of ALK reduced tumor growth of xenografts in athymic nude mice and prolonged survival of the animals because of increased apoptosis in the tumors. These findings directly implicate ALK signaling as a rate-limiting factor in the growth of glioblastoma multiforme and suggest potential utility of therapeutic targeting of ALK.